How an AI bust could blow up the 2028 race

But the 2028 presidential race would also be upended. An AI crash could rewire both party primaries by superseding all other ...
Le Lézard

Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK ...
Pharmabiz

Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS

Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS ...

F. Hoffmann-La Roche Ltd: Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...
Taiwan News

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Fenebrutinib numerically reduced the risk of disability progression by 12% compared to OCREVUS as early as 24 weeks; additional analysis showed potential benefit in upper limb function Fenebrutinib ...
DecorHint on MSN

This Funky California Art Neighborhood Feels Straight Out Of A Dream

Few places manage to blend raw creativity with coastal charm quite like one particular stretch of Southern California ...
pharmaphorum

PTC pulls file for Duchenne therapy on FDA feedback

In a statement, PTC's chief executive, Matthew Klein, said the company had decided to pull the filing for Translarna (ataluren) as a treatment for nonsense mutation DMD after the FDA said it was ...
pharmaphorum

Lundbeck preps phase 3 for migraine prevention drug

Results from the phase 2b PROCEED trial of intravenous bocunebart (also known as Lu AG09222) showed that the drug was able to cut the number of monthly migraine days (MMD) compared to placebo, with a ...
Team-BHP

Mahindra Scorpio-N pickup truck to be launched in 2027

Unveiled in 2023, the Global Pik Up Vision concept previewed a future pickup truck based on the Mahindra Scorpio-N. It has ...

AI dollars boosting Jackson, Bean

AI PAC: A political action committee backed by some of the biggest names in artificial intelligence is investing heavily in ...
pharmaphorum

Hudson out at Sanofi, as Belén Garijo named CEO

Sanofi has announced a change of leadership, with former Merck KGaA chief executive Belén Garijo taking the helm of the French group from Paul Hudson, whose contract will not be renewed.

Handsome at Any Cost

Braden Peters, known as Clavicular, has emerged as a beacon for a group of narcissistic, status-obsessed young men. He wants to take his fixation with “looksmaxxing” mainstream.